Literature DB >> 21150796

Racial differences in surgeons and hospitals for endometrial cancer treatment.

Katrina Armstrong1, Thomas C Randall, Daniel Polsky, Elizabeth Moye, Jeffrey H Silber.   

Abstract

PURPOSE: To determine whether (1) black and white women with endometrial cancer were treated by different surgical specialties and in different types of hospitals and (2) differences in specialty and hospital type contributed to racial differences in survival.
METHODS: Retrospective cohort study of 12,307 women aged 65 years and older who underwent surgical treatment of endometrial cancer between 1991 and 1999 in the 11 Surveillance Epidemiology and End Results registries.
RESULTS: Black women were more likely to have a gynecologic oncologist to perform their surgery and to be treated at hospitals that were higher volume, larger, teaching, National Cancer Institute centers, urban, and where a greater proportion of the surgeries were performed by a gynecologic oncologist. In unadjusted models, black women were over twice as likely as white women who died because of cancer (hazards ratio [HR]: 2.33), but nearly all of the initial racial difference in survival was explained by differences in cancer stage, and grade as well as age and comorbidities at presentation (adjusted HR: 1.10). Surgical specialty was not associated with survival and, of the hospital characteristics studied, only surgical volume was associated with survival (P < 0.005). Adjusting for hospital characteristics did not change the racial difference in survival (HR: 1.10). Adjustment for the specific hospital where the woman was treated eliminated the association between race and surgeon specialty and slightly widened the residual racial difference in survival (HR: 1.23 vs. 1.10).
CONCLUSIONS: In contrast to several studies suggesting that blacks with breast cancer, colon cancer, or cardiovascular disease are treated in hospitals with lower quality indicators, black women diagnosed with endometrial cancer in Surveillance Epidemiology and End Results regions between 1991 and 1999 were more likely to be treated by physicians with advanced training and in high volume, large, urban, teaching hospitals. However, except for a modest association with hospital surgical volume, these provider and hospital characteristics were largely unrelated to survival for women with endometrial cancer. The great majority of the difference in survival was explained by differences in tumor and clinical characteristics at presentation.

Entities:  

Mesh:

Year:  2011        PMID: 21150796      PMCID: PMC3332036          DOI: 10.1097/MLR.0b013e3182019123

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  22 in total

1.  Racial residential segregation: a fundamental cause of racial disparities in health.

Authors:  D R Williams; C Collins
Journal:  Public Health Rep       Date:  2001 Sep-Oct       Impact factor: 2.792

2.  Ovarian cancer staging: does it require a gynecologic oncologist?

Authors:  A R Mayer; S K Chambers; E Graves; C Holm; P C Tseng; B E Nelson; P E Schwartz
Journal:  Gynecol Oncol       Date:  1992-11       Impact factor: 5.482

3.  Primary care physicians who treat blacks and whites.

Authors:  Peter B Bach; Hoangmai H Pham; Deborah Schrag; Ramsey C Tate; J Lee Hargraves
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

4.  Health care for black and poor hospitalized Medicare patients.

Authors:  K L Kahn; M L Pearson; E R Harrison; K A Desmond; W H Rogers; L V Rubenstein; R H Brook; E B Keeler
Journal:  JAMA       Date:  1994-04-20       Impact factor: 56.272

5.  National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival.

Authors:  H N Nguyen; H E Averette; W Hoskins; M Penalver; B U Sevin; A Steren
Journal:  Cancer       Date:  1993-12-15       Impact factor: 6.860

6.  Racial and ethnic differences in time to acute reperfusion therapy for patients hospitalized with myocardial infarction.

Authors:  Elizabeth H Bradley; Jeph Herrin; Yongfei Wang; Robert L McNamara; Tashonna R Webster; David J Magid; Martha Blaney; Eric D Peterson; John G Canto; Charles V Pollack; Harlan M Krumholz
Journal:  JAMA       Date:  2004-10-06       Impact factor: 56.272

7.  The impact of subspecialty training on the management of advanced ovarian cancer.

Authors:  S M Eisenkop; N M Spirtos; T W Montag; R H Nalick; H J Wang
Journal:  Gynecol Oncol       Date:  1992-11       Impact factor: 5.482

8.  Hospital factors and racial disparities in mortality after surgery for breast and colon cancer.

Authors:  Tara M Breslin; Arden M Morris; Niya Gu; Sandra L Wong; Emily V Finlayson; Mousumi Banerjee; John D Birkmeyer
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

9.  Differences in treatment and outcome between African-American and white women with endometrial cancer.

Authors:  Thomas C Randall; Katrina Armstrong
Journal:  J Clin Oncol       Date:  2003-11-15       Impact factor: 44.544

10.  The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma.

Authors:  S Kehoe; J Powell; S Wilson; C Woodman
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

View more
  9 in total

1.  Racial disparities in changing to a high-volume urologist among men with localized prostate cancer.

Authors:  Craig Evan Pollack; Justin E Bekelman; Andrew J Epstein; Kaijun Liao; Yu-Ning Wong; Katrina Armstrong
Journal:  Med Care       Date:  2011-11       Impact factor: 2.983

2.  Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer.

Authors:  Anne Marie McCarthy; Mirar Bristol; Susan M Domchek; Peter W Groeneveld; Younji Kim; U Nkiru Motanya; Judy A Shea; Katrina Armstrong
Journal:  J Clin Oncol       Date:  2016-05-09       Impact factor: 44.544

Review 3.  Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology.

Authors:  Yvonne Collins; Kevin Holcomb; Eloise Chapman-Davis; Dineo Khabele; John H Farley
Journal:  Gynecol Oncol       Date:  2014-01-07       Impact factor: 5.482

4.  Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons.

Authors:  Jamie N Bakkum-Gamez; Nicolas Wentzensen; Matthew J Maurer; Kieran M Hawthorne; Jesse S Voss; Trynda N Kroneman; Abimbola O Famuyide; Amy C Clayton; Kevin C Halling; Sarah E Kerr; William A Cliby; Sean C Dowdy; Benjamin R Kipp; Andrea Mariani; Ann L Oberg; Karl C Podratz; Viji Shridhar; Mark E Sherman
Journal:  Gynecol Oncol       Date:  2015-02-10       Impact factor: 5.482

Review 5.  Disparities in gynecologic cancer incidence, treatment, and survival: a narrative review of outcomes among black and white women in the United States.

Authors:  Mary Towner; J Julie Kim; Melissa A Simon; Daniela Matei; Dario Roque
Journal:  Int J Gynecol Cancer       Date:  2022-07-04       Impact factor: 4.661

6.  Aberrantly activated pSTAT3-Ser727 in human endometrial cancer is suppressed by HO-3867, a novel STAT3 inhibitor.

Authors:  Brent J Tierney; Georgia A McCann; Shan Naidu; Kellie S Rath; Uksha Saini; Ross Wanner; Periannan Kuppusamy; Adrian Suarez; Paul J Goodfellow; David E Cohn; Karuppaiyah Selvendiran
Journal:  Gynecol Oncol       Date:  2014-07-16       Impact factor: 5.482

7.  Lack of improvement in survival rates for women under 50 with endometrial cancer, 2000-2011.

Authors:  Ana M Rodriguez; Kathleen M Schmeler; Yong-Fang Kuo
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-15       Impact factor: 4.553

8.  Disparities and interventions in the timeliness of endometrial cancer diagnosis and treatment in the United States: a scoping review protocol.

Authors:  Avonne E Connor; Christopher C Destephano; Anna J Najor; Dyda Dao; Jamie N Bakkum-Gamez; Mark E Sherman
Journal:  Syst Rev       Date:  2021-04-13

Review 9.  Disparities in Gynecological Malignancies.

Authors:  Sudeshna Chatterjee; Divya Gupta; Thomas A Caputo; Kevin Holcomb
Journal:  Front Oncol       Date:  2016-02-22       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.